Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.
Showing 25–48 of 88
Circulating small RNAs, particularly nine piRNAs, predict two-year survival in older adults with greater accuracy than age and clinical factors alone, with experimental evidence suggesting reduced piRNA levels associate with extended lifespan. These findings identify specific small RNA signatures as measurable biomarkers and potential therapeutic targets for longevity interventions.
Genflow's SIRT6 gene therapy demonstrated superior survival and functional improvements in aged beagles across multiple endpoints, including muscle preservation, frailty reduction, and quality of life measures. This interim data from a proof-of-concept trial establishes preliminary evidence that SIRT6 activation may mitigate age-related functional decline, with potential implications for human therapeutic development.
Rznomics' RZ-001, an RNA-editing therapeutic targeting hepatocellular carcinoma, received FDA Regenerative Medicine Advanced Therapy designation based on Phase 1b/2a safety and efficacy data. This regulatory milestone accelerates development pathways for a precision oncology candidate using trans-splicing ribozyme technology to selectively target cancer cells.
Scribe Therapeutics and Eli Lilly have achieved a second development milestone in their partnership to create in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases. The progress validates their X-Editor platform and data-driven optimization approach for precise gene editing, positioning these therapies to address conditions with limited treatment options.
Researchers developed a lipid nanoparticle that delivers mRNA encoding TRIM11, a natural ligase that disaggregates tau tangles, across the blood-brain barrier in mouse models of Alzheimer's disease. Treatment produced sustained cognitive and behavioral restoration comparable to wild-type mice, with reduction in tau pathology and neuroinflammatory markers.
The oligonucleotide therapeutics market is projected to reach $17.7 billion by 2030, growing at 19.7 percent annually from 2025. Advances in RNA-targeting medicines and delivery technologies are enabling precision approaches to neurological disorders and rare diseases where conventional pharmaceuticals have limited efficacy.
Interferon-gamma (IFN-γ), a common immune signaling molecule, emerges as a blood-based biomarker capable of distinguishing Alzheimer's disease from healthy aging with high accuracy, particularly in individuals carrying the APOE ε4 genetic variant. The finding suggests a scalable pathway for early detection and monitoring, shifting the disease profile toward immune-driven pathology.
Electrocardiogram-derived heart age models show moderate agreement with chronological age but demonstrate significant individual variation, with predictive accuracy for cardiovascular outcomes varying substantially depending on the specific model used. This suggests ECG-based age estimates require careful interpretation and cannot yet replace traditional risk assessment tools.
Cyclo Therapeutics secured an exclusive MIT patent license for cyclodextrin use in ApoE4-positive Alzheimer's disease patients, a population representing 50-70% of Alzheimer's cases. The mechanism targets cholesterol transport in the central nervous system to address amyloid and tau pathology, with Phase 3 results expected in Q3 2026.
Over 40 companies are developing more than 50 drug candidates for sickle cell disease across gene therapy, gene editing, and small molecule approaches, with several candidates in late-stage clinical trials. This expansion of therapeutic options addresses a genetic blood disorder that directly compromises oxygen delivery, energy production, and tissue regeneration—core drivers of age-related pathology.
Airna initiated a Phase 1 trial of AIR-001, an RNA-editing therapeutic designed to correct the genetic mutation underlying alpha-1 antitrypsin deficiency by restoring functional AAT protein production. This approach addresses a monogenic disorder affecting both pulmonary and hepatic function, representing a mechanistic advance in treating a condition with significant longevity impact across multiple organ systems.
Astellas exercised a licensing option for a Dyno Therapeutics engineered AAV capsid designed for skeletal muscle gene delivery, marking validation of AI-driven capsid engineering for tissue-targeted viral vectors. The technology addresses a fundamental limitation in gene therapy: achieving efficient delivery to specific tissues while maintaining manufacturability.
Four emerging research areas—paternal exercise effects on offspring via sperm signaling molecules, mRNA vaccine applications in cancer treatment, non-invasive sensory stimulation for neurodegeneration, and autonomic nervous system dysfunction as a common aging mechanism—establish mechanistic pathways through which upstream interventions influence downstream health outcomes across generations and disease states.
GenSight Biologics is advancing LUMEVOQ (GS010), a gene therapy targeting ND4 mitochondrial mutations in Leber hereditary optic neuropathy, through early access programs in France, Israel, and the United States while conducting the REVISE dose-ranging clinical study. This represents progress toward treating a rare genetic form of progressive vision loss by addressing the underlying mitochondrial dysfunction.
The global ALS therapeutics market is projected to more than double from $812 million in 2024 to $1.964 billion by 2035, driven by innovation in disease-modifying and neuroprotective approaches including antisense oligonucleotides, gene therapies, and biologics. This expansion reflects a fundamental shift in treatment philosophy from symptomatic management toward interventions that address underlying neurodegeneration.
This article reports Alnylam Pharmaceuticals' 2025 financial performance—$2.987 billion in annual revenue with 81% year-over-year growth and achievement of profitability. The financial success reflects commercial adoption of RNA interference therapeutics for rare genetic and cardiometabolic diseases, which has direct relevance to the development and accessibility of precision therapies that address underlying genetic drivers of age-related conditions.
Epigenetic aging clocks measure chemical changes to DNA to estimate biological age, but they are research tools designed for population-level study, not reliable for individual health assessment. Consumer products marketing these tests as personal health indicators misrepresent their validity and clinical utility.
Commercially available biological age tests based on epigenetic markers lack clinical validity, standardized accuracy measures, and actionable clinical utility. When physicians recommend them, they abandon evidence-based practice in favor of customer satisfaction, potentially replacing genuine health assessment with unfounded reassurance or unnecessary anxiety.
Biological age clocks derived from DNA methylation patterns show significant day-to-day fluctuations within individuals, independent of actual chronological aging. This instability raises critical questions about their reliability for clinical application and longevity intervention assessment.
Klotho Neurosciences has developed AI-powered genomics tests that measure biological age through DNA methylation and mRNA analysis of longevity-associated genes. This approach enables more precise stratification in clinical trials for neurodegenerative diseases, reducing confounding variables that arise when chronological and biological age diverge.
Researchers developed OMICmAge, a DNA-methylation-based biological aging clock integrating proteomic and metabolomic data from 31,000 electronic medical records. The measure predicts mortality and age-related disease risk with performance comparable to or superior to existing biomarkers, offering a scalable tool for quantifying biological aging status.
OMICmAge integrates multi-omics data with DNA methylation to create a biological age measure that predicts disease and mortality risk more accurately than chronological age alone. This approach enables risk stratification based on measurable molecular signatures rather than calendar years.
Longitudinal changes in epigenetic clocks—molecular markers of biological age—independently predict mortality over 24 years, independent of baseline biological age. This establishes that the rate of epigenetic change itself, not just absolute age status, carries clinically actionable information for longevity assessment.
Epigenetic aging—the divergence between chronological age and biological age—emerges as a measurable marker influenced by both genetic predisposition and modifiable molecular factors. Understanding these mechanisms provides actionable insight into why some individuals age more slowly at the cellular level and how interventions targeting epigenetic signatures may extend healthspan.
